Cargando…

Few new drugs deserve expedited regulatory treatment

Detalles Bibliográficos
Autor principal:	Darrow, Jonathan J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2021
Materias:	Perspectives on Expedited FDA Approval
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390900/ https://www.ncbi.nlm.nih.gov/pubmed/33908278 http://dx.doi.org/10.18553/jmcp.2021.27.5.685

Ejemplares similares

FDA expedited approval and implications for rational formulary and health plan design
por: Ferries, Erin A, et al.
Publicado: (2021)

Commentary: Expedited Regulatory Review of Low-Value Drugs
por: Darrow, Jonathan J., et al.
Publicado: (2020)

A Novel Hydrogen Sulfide Prodrug, SG1002, Promotes Hydrogen Sulfide and Nitric Oxide Bioavailability in Heart Failure Patients
por: Polhemus, David J., et al.
Publicado: (2015)

FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy
por: Bhatnagar, Vishal, et al.
Publicado: (2017)

FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis
por: Kasamon, Yvette L., et al.
Publicado: (2018)

FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma
por: Kasamon, Yvette L., et al.
Publicado: (2017)

FDA Approval Summary: Brentuximab Vedotin in First‐Line Treatment of Peripheral T‐Cell Lymphoma
por: Richardson, Nicholas C., et al.
Publicado: (2019)

Benefit‐Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib
por: Pelosof, Lorraine, et al.
Publicado: (2018)

FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim‐Chester Disease with the BRAFV600 Mutation
por: Oneal, Patricia A., et al.
Publicado: (2018)

FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B‐Cell Acute Lymphoblastic Leukemia
por: Pulte, E. Dianne, et al.
Publicado: (2018)

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy
por: Suzman, Daniel L., et al.
Publicado: (2018)

FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‐Containing Chemotherapy
por: Ning, Yang‐Min, et al.
Publicado: (2017)

FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond
por: Pai‐Scherf, Lee, et al.
Publicado: (2017)

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
por: Kazandjian, Dickran, et al.
Publicado: (2016)

Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer
por: Kazandjian, Dickran, et al.
Publicado: (2016)

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome
por: Le, Robert Q., et al.
Publicado: (2018)

FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers Harboring BRAF V600E Mutations
por: Odogwu, Lauretta, et al.
Publicado: (2018)

FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum‐Containing Chemotherapy
por: Larkins, Erin, et al.
Publicado: (2017)

FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1
por: Sul, Joohee, et al.
Publicado: (2016)

FDA Benefit‐Risk Assessment of Osimertinib for the Treatment of Metastatic Non‐Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation
por: Odogwu, Lauretta, et al.
Publicado: (2017)

An Analysis of Seventy-Three Appeals
Publicado: (1921)

Tele-health in pediatric ophthalmology: Promises and pitfalls
por: Chakrabarti, Rahul, et al.
Publicado: (2021)

Mucormycosis in COVID-19 patients
por: Sundaram, Natarajan, et al.
Publicado: (2021)

Who Deserves Health Care in a Global Pandemic?
por: Gagnon, Monica, et al.
Publicado: (2021)

FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
por: Pulte, Elizabeth Dianne, et al.
Publicado: (2018)

FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1
por: Fashoyin‐Aje, Lola, et al.
Publicado: (2018)

FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti‐Angiogenic Therapy and Exploratory Predictive Biomarker Analysis
por: Xu, James Xunhai, et al.
Publicado: (2017)

The Food and Drug Administration Office of Women's Health: Impact of Science on Regulatory Policy: An Update
por: Elahi, Merina, et al.
Publicado: (2016)

Clinical characteristics associated with COVID-19 severity in California
por: Rubin, Samuel J. S., et al.
Publicado: (2020)

Leveraging community engaged research partnerships for crisis and emergency risk communication to vulnerable populations in the COVID-19 pandemic
por: Wieland, Mark L., et al.
Publicado: (2020)

Immediate impact of the COVID-19 pandemic on CTSA TL1 and KL2 training and career development
por: McCormack, Wayne T., et al.
Publicado: (2020)

Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study
por: Kesselheim, Aaron S, et al.
Publicado: (2015)

1% Tirbanibulin Ointment for the Treatment of Actinic Keratoses
por: Dao, Diem-Phuong D., et al.
Publicado: (2021)

Global Standards to Expedite Learning From Medical Research Data
por: Hudson, Lynn D., et al.
Publicado: (2018)

TFDA takes actions to expedite the development of COVID-19 vaccines
por: Liu, Sam Chi-Hao, et al.
Publicado: (2022)

Endovascular Mechanical Thrombectomy for Acute Ischemic Stroke: A New Standard of Care
por: Ding, Dale
Publicado: (2015)

Citizen-led expeditions can generate scientific knowledge and prospects for researchers
por: Sampaio, Eduardo, et al.
Publicado: (2022)

HIV and adolescent girls and young women in sub‐Saharan Africa: A call for expedited action to reduce new infections
por: Murewanhema, Grant, et al.
Publicado: (2022)

Help for the Deserving
por: Lewisburg, J. H. M.
Publicado: (1876)

Expedited COVID-19 vaccine trials: a rat-race with challenges and ethical issues
por: Kamble, Prathamesh Haridas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_19ql9sa7qu90kvs604c412rcsg